about
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive suCXCL12 expression by healthy and malignant ovarian epithelial cells.Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriersThe contribution of germline rearrangements to the spectrum of BRCA2 mutationsPeritoneal pseudomyxoma arising from the urachus.Uptake of a randomized breast cancer prevention trial comparing letrozole to placebo in BRCA1/2 mutations carriers: the LIBER trial.Adherence to guidelines in gynecologic cancer surgery.Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary.Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix.Phase I study of irinotecan and cisplatin in combination with pelvic radiotherapy in the treatment of locally advanced cervical cancer: A GINECO trial.Childhood anaplastic large cell lymphoma Ki-1/CD30: clinicopathologic features of 19 cases.[Intraperitoneal chemotherapy in the treatment of advanced ovarian cancer].Weekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GIQuality indicators in ovarian cancer surgery: report from the French Society of Gynecologic Oncology (Societe Francaise d'Oncologie Gynecologique, SFOG).A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial.Prognostic relevance of celiac lymph node involvement in ovarian cancer.Spontaneous regression of peritoneal carcinomatosis in a borderline ovarian tumourPitfalls of CA-125 levels in the preoperative work-up of ovarian massesPelvic lymph node dissection via a lateral extraperitoneal approach: description of a technique[Preservation of fertility in gynaecologic cancers]Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre studyLaparoscopic management of an isolated ovarian metastasis on a transposed ovary in a patient treated for stage IB1 adenocarcinoma of the cervixFrench women's breast self-examination practices with time after undergoing BRCA1/2 genetic testingA phase I study of ixabepilone in combination with epirubicin in patients with metastatic breast cancerA comparative study of laparoscopic extraperitoneal lymphadenectomy [correction of laparoscopy] with the use of ultrasonically activated shearsVariation in breast cancer risk with mutation position, smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carrier cohort (GENEPSO)[Towards a new standard in cytoreductive surgery for advanced ovarian cancer][Pharmacological bases of intraperitoneal chemotherapy][Importance of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer]Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristicsUpdated results from OCTAVIA (front-line bevacizumab, carboplatin and weekly paclitaxel therapy for ovarian cancer)
P50
Q33391949-6D834491-4B48-4EDB-B5B0-9D4B9245BBB3Q33410174-B2BBB09A-67A3-40C8-8322-529B8290FB1FQ33416659-8111E922-40B3-487B-A9B7-CF4BAB8AEF24Q33848551-7EC558B7-9F2D-4D94-A381-8D609CFCCD0FQ34801008-3B80787C-A98A-438A-B205-B2A79C3F0C01Q36930173-83AF7459-EEF1-4B07-A4DC-F171BE2DFA46Q37699827-0CA3387A-618F-4C6C-98FC-B87C7A7867D5Q37955050-7E04EC54-FDA5-4054-AB8D-279462F34EA9Q38262152-BCA22457-0462-43B3-9426-95068911CB64Q38262333-44BCCFF7-1CD3-412D-B76A-133A772B897EQ38262346-41C06330-8FDC-4D14-84D3-C2BF69C6868CQ39892268-E6B37B7B-6BB0-4D4D-8AE1-60D871C28A62Q40706382-73706CB9-3A44-42B8-8CC2-B38CE7685CBCQ43180037-9F748779-AEEE-4382-9087-C8E3A78DA060Q44117882-98A08FE7-F0A5-493D-910F-3DFD797D6DC9Q45385477-45798B6B-DEE3-4E8E-8D3E-64FD0848DC1BQ46033040-C206A2A3-966A-4E26-969E-B2947086C782Q46708749-86D0822B-4E63-45C8-8947-ED33D39CEB52Q48413812-EC78F439-0CB2-4B4D-AB48-36C35716479FQ50878372-07E9A8F0-963D-4C30-8AAD-94622EB8C3FFQ53144473-1C67EDDA-DCA1-471A-B49D-E4AF9E4296DBQ54529334-8F7E9EA6-B651-4624-89AC-8704CDBAD425Q79795532-9C9FEE9C-44F3-4B2D-ADB9-D716D1E4616EQ80508837-47905594-1C51-4DEA-B9CC-BF200F7B89F3Q80655251-ECFE22A0-DF55-41F8-8115-904D507AD03AQ81426357-71F1B5F7-3C5B-4BF4-A332-1B3E6FFA897AQ82662065-A01D9266-46A0-43D6-BD60-6477062D9CC6Q83095225-2651C725-C424-4416-8BB0-51A5685BF97EQ83476773-86207B37-1CB2-4011-B26D-D22344D91F8CQ84167623-F27531AA-A748-4ADD-BE07-F28E2EDF5B7CQ84206494-7F45A4DE-2004-49B4-8CB3-747ECA77222FQ84562970-A1C8B7BC-0442-4B5D-9379-EE8900131654Q84910358-92104F50-29BC-4B57-A71C-5699707EE129Q84923826-7AC08C0C-611F-4FE9-95C3-ACB97847BCDFQ84964539-593A7B59-CC66-48FE-BD42-186A0A5B465FQ85157505-4670D2EF-02B9-481C-A772-6DB8937C556EQ87087502-A09836A3-C333-4377-8B5B-3472A1A26FCB
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Laurence Gladieff
@ast
Laurence Gladieff
@en
Laurence Gladieff
@es
Laurence Gladieff
@nl
type
label
Laurence Gladieff
@ast
Laurence Gladieff
@en
Laurence Gladieff
@es
Laurence Gladieff
@nl
prefLabel
Laurence Gladieff
@ast
Laurence Gladieff
@en
Laurence Gladieff
@es
Laurence Gladieff
@nl
P106
P31
P496
0000-0002-6980-9719